3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Carcinoma, Renal Cell
2
Brain Neoplasms
2
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neuroendocrine Tumors (pNET)
1
Oropharyngeal Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Melanoma
1
Lymphoma, Mantle-Cell
1
Head and Neck Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Breast Carcinoma In Situ
1
Anus Neoplasms
1
Anatomic Stage II Breast Cancer AJCC v8
1
Anal Canal Carcinoma
1
Interventions
X-Rays
5
Phantoms, Imaging
5
Nuclear Medicine Department, Hospital
5
Magnetic Resonance Spectroscopy
5
Specimen Handling
4
Biopsy
4
ulixertinib
2
tipifarnib
2
selpercatinib
2
larotrectinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
tazemetostat
1
talazoparib
1
palbociclib
1
olaparib
1
irinotecan sucrosofate
1
fludarabine phosphate
1
fludarabine
1
cabozantinib
1
Vemurafenib
1
Temozolomide
1
Pharmacogenomic Variants
1
Mesna
1
LY3023414
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Hepatoblastoma
×
Watchful Waiting
×
30 days
×
Clear all
No trials found.